The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey



      The course of hereditary angioedema (HAE) and the efficacy and safety of human C1-INH concentrate were appraised during pregnancy and the postpartum period, in patients with HAE.

      Study design

      Retrospective analysis of clinical data on 118 pregnancies (82 full-term and 36 abortions) in 41 female patients, extracted from the National HAE Registry, medical charts and patient diaries.


      HAE attack frequency increases in 48% of pregnancies, whereas 33% of pregnancies were associated with mitigation of clinical signs and 19% of the pregnancies had no influence on the course of HAE, as compared to disease severity seen during the 2-year period preceding the pregnancy. During 46 full-term pregnancies, 26 patients reported attacks; 52% of these occurred in the third trimester. Abdominal attacks are the most common presentation of HAE during pregnancy. Attack number was significantly higher in patients who had sustained their initial attack before 8 years of age. Attack number increased during the third trimester if the fetus was afflicted by HAE. During the postpartum period, attacks occurred in 6/82 pregnancies. Patients received 91 vials of C1-INH concentrate altogether for the relief of acute attacks and for short- or long-term prophylaxis during pregnancy. This therapy was effective in all instances; no adverse effects were observed.


      Pregnancy can either aggravate or mitigate edematous attacks, or alternatively, it may have no influence on the severity of the disease. According to our experience, C1-INH concentrate is an effective and safe therapeutic option during pregnancy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Agostoni A.
        • Aygoren-Pursun E.
        • Binkley K.E.
        • et al.
        Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.
        J Allergy Clin Immunol. 2004; 114: S51-S131
        • Carugati A.
        • Pappalardo E.
        • Zingale L.C.
        • Cicardi M.
        C1-inhibitor deficiency and angioedema.
        Mol Immunol. 2001; 38: 161-173
        • Frank M.M.
        Hereditary angioedema: the clinical syndrome and its management in the United States.
        Immunol Allergy Clin North Am. 2006; 26: 653-668
        • Farkas H.
        • Fust G.
        • Fekete B.
        • Karadi I.
        • Varga L.
        Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema.
        Lancet. 2001; 358: 1695-1696
        • Bouillet L.
        • Ponard D.
        • Drouet C.
        • Jullien D.
        • Massot C.
        Angioedema and oral contraception.
        Dermatology. 2003; 206: 106-109
        • Sanhueza P.I.
        Contraception in hereditary angioedema.
        Fertil Steril. 2008; 90 (e21–e22): 2015
        • Bouillet L.
        • Longhurst H.
        • Boccon-Gibod I.
        • et al.
        Disease expression in women with hereditary angioedema.
        Am J Obstet Gynecol. 2008; 199 (e1–e4): 484
        • Bowen T.
        • Cicardi M.
        • Bork K.
        • et al.
        Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.
        Ann Allergy Asthma Immunol. 2008; 100: S30-40
        • Farkas H.
        • Jakab L.
        • Temesszentandrasi G.
        • et al.
        Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.
        J Allergy Clin Immunol. 2007; 120: 941-947
        • Gompels M.M.
        • Lock R.J.
        • Abinun M.
        • et al.
        C1 inhibitor deficiency: consensus document.
        Clin Exp Immunol. 2005; 139: 379-394
        • Boulos A.N.
        • Brown R.
        • Hukin A.
        • Williams R.M.
        Danazol prophylaxis for delivery in hereditary angioneurotic oedema.
        Br J Obstet Gynaecol. 1994; 101: 1094-1095
        • Caliskaner Z.
        • Ozturk S.
        • Gulec M.
        • Dede M.
        • Erel F.
        • Karaayvaz M.
        A successful pregnancy and uncomplicated labor with C1INH concentrate prophylaxis in a patient with hereditary angioedema.
        Allergol Immunopathol (Madr). 2007; 35: 117-119
        • Chinniah N.
        • Katelaris C.H.
        Hereditary angioedema and pregnancy.
        Aust N Z J Obstet Gynaecol. 2009; 49: 2-5
        • Cohen A.J.
        • Laskin C.
        • Tarlo S.
        C1 esterase inhibitor in pregnancy.
        J Allergy Clin Immunol. 1992; 90: 412-413
        • Cox M.
        • Holdcroft A.
        Hereditary angioneurotic oedema: current management in pregnancy.
        Anaesthesia. 1995; 50: 547-549
        • Duvvur S.
        • Khan F.
        • Powell K.
        Hereditary angioedema and pregnancy.
        J Matern Fetal Neonatal Med. 2007; 20: 563-565
        • Ferlazzo B.
        • Barrile A.
        • Bonanno D.
        • et al.
        Clinical contribution to the problem of correlations between hereditary angioneurotic edema and pregnancy.
        Minerva Ginecol. 1990; 42: 351-356
        • Gorman P.J.
        Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate.
        Can Fam Physician. 2008; 54: 365-366
        • Hermans C.
        Successful management with C1-inhibitor concentrate of hereditary angioedema attacks during two successive pregnancies: a case report.
        Arch Gynecol Obstet. 2007; 276: 271-276
        • Kreuz W.
        • Martinez-Saguer I.
        • Rusicke E.
        • Aygören-Pürsün E.
        • Klingebiel T.
        Management of HAE patients during pregnancy and delivery – a prospective 12-years follow up.
        J Allergy Clin Immunol. 2008; ([Abstract 379]): S98
        • Nathani F.
        • Sullivan H.
        • Churchill D.
        Pregnancy and C1 esterase inhibitor deficiency: a successful outcome.
        Arch Gynecol Obstet. 2006; 274: 381-384
        • Raychaudhuri K.
        • Buck P.
        • Pumphrey R.S.
        Termination of pregnancy in a patient with hereditary angioedema.
        Br J Hosp Med. 1997; 58: 287-288
        • Visy B.
        • Fust G.
        • Varga L.
        • et al.
        Sex hormones in hereditary angioneurotic oedema.
        Clin Endocrinol (Oxf). 2004; 60: 508-515
        • Cichon S.
        • Martin L.
        • Hennies H.C.
        • et al.
        Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.
        Am J Hum Genet. 2006; 79: 1098-1104
        • Prada A.E.
        • Zahedi K.
        • Davis 3rd., A.E.
        Regulation of C1 inhibitor synthesis.
        Immunobiology. 1998; 199: 377-388
        • Nielsen E.W.
        • Gran J.T.
        • Straume B.
        • Mellbye O.J.
        • Johansen H.T.
        • Mollnes T.E.
        Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses.
        J Intern Med. 1996; 239: 119-130
        • Postnikoff I.M.
        • Pritzker K.P.
        Hereditary angioneurotic edema: an unusual case of maternal mortality.
        J Forensic Sci. 1979; 24: 473-478